Skip to content

Application of the Dietary Inflammatory Index in Predicting the Progression of Gastric Precancerous Lesions and Risk Stratification Among High-Risk Populations

Application of the Dietary Inflammatory Index in Predicting the Progression of Gastric Precancerous Lesions and Risk Stratification Among High-Risk Populations

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500113463
Enrollment
Unknown
Registered
2025-11-28
Start date
2026-01-01
Completion date
Unknown
Last updated
2025-12-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric Precancerous Lesions

Interventions

Low-DII group:None
High-DII group:None

Sponsors

The First People's Hospital of Xiaoshan Distric, Hangzhou
Lead Sponsor

Eligibility

Sex/Gender
All
Age
45 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.Age between 45 and 75 years; 2.Individuals meeting the definition of high-risk population for gastric cancer according to the Chinese Guideline for Screening, Early Detection and Early Treatment of Gastric Cancer (2022 Edition), meeting at least one of the following conditions: (1) Histologically confirmed chronic atrophic gastritis or intestinal metaplasia; (2) Current or previous Helicobacter pylori infection (including eradicated cases); (3) Family history of gastric cancer in first-degree relatives; (4) Unhealthy lifestyle factors such as high-salt diet, smoking, or heavy alcohol consumption; (5) Long-term residence in a high-incidence area of gastric cancer. 3.Able to complete follow-up visits, endoscopic examinations, and food frequency questionnaire (FFQ) assessments; 4.Willing to participate and sign written informed consent.

Exclusion criteria

Exclusion criteria: 1.Presence of any grade of gastric epithelial dysplasia (low- or high-grade) at baseline endoscopy; 2.History of gastric, esophageal, or other gastrointestinal malignancies; 3.Previous partial or total gastrectomy; 4.Severe systemic diseases such as decompensated liver cirrhosis, chronic renal failure, or severe cardiovascular/cerebrovascular diseases; 5.Pregnant or lactating women; 6.Use of antibiotics, probiotics, or proton pump inhibitors within 3 months prior to enrollment that may affect gastric microbiota; 7.Inability to complete follow-up or unwillingness to participate.

Design outcomes

Primary

MeasureTime frame
Histological progression rate of gastric mucosal lesions;

Countries

China

Contacts

Public ContactYihui Shi

The First People's Hospital of Xiaoshan Distric, Hangzhou

1434463457@qq.com+86 150 5716 4510

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026